Top Movers: Novogen Limited (ADR) (NASDAQ:NVGN), Gilead Sciences, Inc.(NASDAQ:GILD)

Lakeway, TX -- (SBWIRE) -- 02/19/2013 -- Bestdamnpennystocks, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Novogen Limited (ADR) (NASDAQ:NVGN) shares were trading up by $2.91 or 139.23 to $5 in the morning session after its experimental anti-ovarian cancer drug CS-6 showed that it was highly active against ovarian cancer stem cells.

Is NVGN after A Solid Pop Up? Find Out Here

In a study designed to find whether the drug would be effective against cancer stem cells, the drug showed potent anti cancer activity against cancer cells.

With CS-6 showing dual activity, it would mark the drug as having significant potential as a comprehensive chemotherapy, targeting both the minority cancer stem cell as well as the majority non stem cells.

The CS-6 belongs to a new class of drug candidates known as super benzopyrans displaying potent anti cancer activity.

A Phase 3 FUSION study evaluating 12- and 16-week courses of therapy with the once-daily nucleotide sofosbuvir plus ribavirin (RBV) in treatment-experienced patients with genotype 2 or 3 chronic hepatitis C virus (HCV) infection who failed prior treatment, of Gilead Sciences, Inc. (NASDAQ:GILD) sends its share up by 96 cents or 2.31% to $42.56 in the morning session.

Will GILD Continue To Trend Higher After The Recent Gain? Find Out Here

Meeting its primary efficacy endpoint of superiority compared to a predefined historic control sustained virologic response rate of 25% the fusion had 50% of patients in the 12-week arm and 73% of patients in the 16-week arm achieving sustained virologic response 12.

“This study demonstrates that all-oral therapy with sofosbuvir provides significant efficacy among difficult-to-treat hepatitis C patients who could not be cured by prior regimens containing pegylated interferon and now have limited treatment options,” said Norbert Bischofberger, PhD, Executive Vice President of Research and Development and Chief Scientific Officer. “With positive results from all four Phase 3 trials now in hand, Gilead is on track to meet its goal of filing regulatory applications in the United States and Europe in the second quarter.”

In the FUSION study, hepatitis C virus genotype 2 or 3 patients who failed prior interferon-based therapy were randomized (1:1) to receive either a 12-week or 16-week course of sofosbuvir 400 mg once daily plus RBV.

About bestdamnpennystocks.com
Best Damn Penny Stocks’ team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by Bestdamnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Bestdamnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in Bestdamnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.